Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 20/20 | 1.00 |
| ▸ | JAK1 | P23458 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 3/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15032935 | 0.92 | JAK3 (1.00) | JAK3JAK1JAK2 | |
| SCHEMBL15032797 | 0.92 | JAK3 (0.90) | JAK3JAK1JAK2 | |
| SCHEMBL15032745 | 0.92 | JAK3 (1.00) | JAK3JAK1JAK2 | |
| SCHEMBL15032929 | 0.92 | JAK3 (1.00) | JAK3JAK1JAK2 | |
| SCHEMBL15032938 | 0.92 | JAK3 (1.00) | JAK3JAK1JAK2 | |
| SCHEMBL15032798 | 0.91 | JAK3 (1.00) | JAK3JAK1JAK2 | |
| SCHEMBL16244955 | 0.91 | JAK3 (1.00) | JAK3JAK1JAK2 | |
| SCHEMBL15032779 | 0.90 | JAK3 (1.00) | JAK3JAK1JAK2 | |
| SCHEMBL15032943 | 0.90 | JAK3 (0.82) | JAK3JAK1JAK2 | |
| SCHEMBL16245047 | 0.90 | JAK3 (0.82) | JAK3JAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788000-B1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-05-30 | — | — | EP | claimed |
| US-8993756-B2 | Pyrrolopyrimidines as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | claimed |
| US-20140349998-A1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIITORS | MERCK SHARP & DOHME CORP. (US) | 2014-11-27 | — | — | US | claimed |
| US-20250000887-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | AKIRABIO, INC. (US) | 2025-01-02 | — | — | US | disclosed |
| US-20240390439-A1 | COMPOSITIONS AND METHODS OF SENECA VALLEY VIRUS (SVV) RELATED CANCER THERAPY | LIFE EDIT THERAPEUTICS, INC. | 2024-11-28 | — | — | US | disclosed |
| EP-4444873-A1 | COMPOSITIONS AND METHODS OF SENECA VALLEY VIRUS (SVV) RELATED CANCER THERAPY | ElevateBio Technologies, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-118354759-A | Compositions comprising 2' -deoxycytidine analogs and their use for treating sickle cell disease, thalassemia and cancer | 阿基拉比奥有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-11938143-B2 | Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers | AKIRABIO, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20240010989-A1 | MEDIUM FOR CULTURING AND EXPANDING NEPHRON PROGENITOR CELLS, METHOD FOR CULTURING AND EXPANDING NEPHRON PROGENITOR CELLS, AND METHOD FOR PRODUCING RENAL ORGANOIDS | KYOTO UNIVERSITY (JP) | 2024-01-11 | — | — | US | disclosed |
| EP-4276172-A1 | MEDIUM FOR CULTURING AND EXPANDING NEPHRON PROGENITOR CELLS, METHOD FOR CULTURING AND EXPANDING NEPHRON PROGENITOR CELLS, AND METHOD FOR PRODUCING RENAL ORGANOIDS | Kyoto University (JP) | 2023-11-15 | — | — | EP | disclosed |
| CN-116802276-A | Culture medium for expansion culture of kidney progenitor cells, method for expansion culture of kidney progenitor cells, and method for producing kidney organoids | 国立大学法人京都大学 | 2023-09-22 | — | — | CN | disclosed |
| WO-2022149615-A1 | CULTURE MEDIUM FOR EXPANSION CULTURE OF NEPHRON PROGENITOR CELL, METHOD FOR PERFORMING EXPANSION CULTURE OF NEPHRON PROGENITOR CELL, AND METHOD FOR PRODUCING KIDNEY ORGANOID | 国立大学法人京都大学 | 2022-07-14 | — | — | WO | disclosed |
| WO-2022149616-A1 | MEDIUM FOR CULTURING AND EXPANDING NEPHRON PROGENITOR CELLS, METHOD FOR CULTURING AND EXPANDING NEPHRON PROGENITOR CELLS, AND METHOD FOR PRODUCING RENAL ORGANOIDS | 国立大学法人京都大学 | 2022-07-14 | — | — | WO | disclosed |
| EP-2788000-B1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-2788000-B1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-05-30 | — | — | EP | disclosed |
| US-8993756-B2 | Pyrrolopyrimidines as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993756-B2 | Pyrrolopyrimidines as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140349998-A1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIITORS | MERCK SHARP & DOHME CORP. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349998-A1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIITORS | MERCK SHARP & DOHME CORP. (US) | 2014-11-27 | — | — | US | disclosed |
| WO-2013085802-A1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349998-A1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIITORS | JAK3, JAK1, JAK2 | JAK3 1/4885JAK1 2/4885JAK2 3/4885 |
| US-11938143-B2 | Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers | TYMP, HBZ, CDA | JAK3 1435/4885JAK1 1483/4885JAK2 779/4885 |
| US-20250000887-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | TYMP, HBZ, HBB | JAK3 1376/4885JAK1 1451/4885JAK2 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.